EGFR and colorectal cancer: Another example is miR-323a-3p, which can target two upregulated tyrosine kinases in gefitinib-resistant colorectal cancer cells (HCT116 GR (gefitinib-resistant GR), LoVo GR, SW620 GR, and HT-29 GR cells)—ErbB and EGFR—representing a potential multi-treatment opportunity to overcome gefitinib resistance and induce apoptosis [72].